PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
Kejing Zhu, Xueting Cheng, Shuman Wang, Hong Zhang, Yu Zhang, Xiong Wang, Yonggang Chen, and Jinhu Wu
Front Endocrinol (Lausanne). 2021; 12: 706909.
PMID: 35126305 DOI: 10.3389/fendo.2021.706909
Background: Prolactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients. In this study, we investigated a protein kinase-PDZ Binding Kinase (PBK)/T-LAK Cell-Originated Protein Kinase (TOPK) as a candidate protein regulating prolactin (PRL) secretion and tumor growth of prolactinomas.